| dc.contributor.author | Sonopo, Molahlehi S. | |
| dc.contributor.author | Zeevaart, Jan R. | |
| dc.contributor.author | Venter, Kobus | |
| dc.contributor.author | Winks, Susan | |
| dc.contributor.author | Marjanovic-Painter, Biljana | |
| dc.date.accessioned | 2017-04-07T11:31:20Z | |
| dc.date.available | 2017-04-07T11:31:20Z | |
| dc.date.issued | 2016 | |
| dc.identifier.citation | Sonopo, M.S. et al. 2016. Carbon-14 radiolabelling and tissue distribution evaluation of a potential anti-TB compound. Journal of labelled compounds and radiopharmaceuticals, 59:264-269. [https://doi.org/10.1002/jlcr.3391] | en_US |
| dc.identifier.issn | 0362-4803 | |
| dc.identifier.issn | 1099-1344 (Online) | |
| dc.identifier.uri | http://hdl.handle.net/10394/21226 | |
| dc.identifier.uri | https://onlinelibrary.wiley.com/doi/abs/10.1002/jlcr.3391 | |
| dc.identifier.uri | https://doi.org/10.1002/jlcr.3391 | |
| dc.description.abstract | This paper describes a five-step synthesis of a carbon-14-labelled pyrazole compound (11). A total of 2.96 MBq of 11 was obtained with the specific activity of 2242.4 MBq/mmol. The radiochemical purity was >99%, and the overall radiochemical yield was 60% based on the [14C6] 4-bromoaniline starting material. Biodistribution results showed that the radiotracer (administrated orally) has a high accumulation in the small intestine, large intestine and liver of both non-infected and tuberculosis (TB)-infected mice. Therefore, this suggests that compound 11 undergoes hepatobiliary clearance. The compound under investigation has been found to be slowly released from the liver between 2 and 8 h. The study revealed that 11 has no affinity for TB cells | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley | en_US |
| dc.title | Carbon-14 radiolabelling and tissue distribution evaluation of a potential anti-TB compound | en_US |
| dc.type | Article | en_US |
| dc.contributor.researchID | 16951484 - Zeevaart, Jan Rijn | |
